Ratings for QuidelOrtho (NASDAQ:QDEL) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) in Q1 CY2025, but sales fell by 2.6% year on year to $692.8 million. The company’s outlook for the full year was close to analysts’ estimates ...
QuidelOrtho Corporation (NASDAQ:QDEL), a prominent player in the Life Science Tools, Diagnostics, and MedTech sectors with a market capitalization of $2.7 billion, has been navigating a complex market ...
QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and ...
QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 80 cents in third-quarter 2025 down from the year-earlier EPS of 85 cents. However, the figure surpassed the Zacks Consensus ...
Welcome to the QuidelOrtho Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participant lines are in a listen-only mode. For those of you participating on the ...
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care ...
―Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results